Neuphoria Therapeutics (NEUP) Retained Earnings (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Retained Earnings for 4 consecutive years, with $218.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Retained Earnings rose 9.54% year-over-year to $218.4 million in Q1 2026; TTM through Mar 2026 was $218.4 million, a 9.54% increase from a year earlier, with the FY2025 full-year figure at $200.2 million, up 0.86% from the prior year.
• Retained Earnings was $218.4 million for Q1 2026 at Neuphoria Therapeutics, roughly flat from $218.3 million in the prior quarter.
• Over five years, Retained Earnings peaked at $218.4 million in Q1 2026 and troughed at -$136.9 million in Q2 2023.
• A 4-year average of $144.0 million and a median of $199.4 million in 2025 frame the typical range for Retained Earnings.
• The widest YoY moves for Retained Earnings: up 5942.54% in 2025, down 0.86% in 2025.
• Over 4 years, Retained Earnings stood at -$136.9 million in 2023, then soared by 97.27% to -$3.7 million in 2024, then surged by 5942.54% to $218.3 million in 2025, then climbed by 0.03% to $218.4 million in 2026.
• The last three Retained Earnings figures came in at $218.4 million (Q1 2026), $218.3 million (Q4 2025), and $203.6 million (Q3 2025), per Business Quant data.